The US Capitol building in Washington, DC.

TCT 2014, the Annual Scientific Symposium of the Cardiovascular Research Foundation, took place September 12-17 in Washington, DC.

Longer duration of triple therapy confers no benefit, trial suggests



aspirin_coated_Credit_Sage_Ross_230.jpg
Aspirin tablets
Credit: Sage Ross

Six weeks of triple anticoagulant therapy may be sufficient in patients who have received a drug-eluting stent. Results of the ISAR-TRIPLE trial revealed no significant differences in net clinical outcomes for patients who received 6 weeks of triple anticoagulant therapy and those who received 6 months of the therapy.... [Read Article]

Shorter duration of DAPT appears safe



thrombus_credit_Andre_E.X._Brown_230.jpg
Thrombus
Credit: Andre E.X. Brown

New research indicates that patients may only need 6 months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent. Results of the SECURITY trial showed that patients had similar outcomes whether they received DAPT for 6 months or a full year. The proportion of patients who met... [Read Article]

Bivalirudin bests heparin in BRIGHT trial



vials_chemo_drugs_Bill_Branson_230.jpg
Vials of drug
Credit: Bill Branson

New results from the BRIGHT trial suggest bivalirudin confers benefits over heparin monotherapy and heparin plus tirofiban for patients with acute myocardial infarction undergoing percutaneous coronary intervention. Patients who received bivalirudin had a significantly lower incidence of net adverse clinical events (NACE), a composite of death from any... [Read Article]